On November 8, 2022,Taysha Gene Therapies, Inc. closed the transaction. The company received $50 million in its final tranche.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.57 USD | -0.39% | +7.53% | +45.20% |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
1,558 JPY | +2.16% | +3.45% | 18.27B | ||
2.57 USD | -0.39% | +7.53% | 481M | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+45.20% | 481M | |
+25.69% | 47.9B | |
+46.90% | 41.42B | |
-3.46% | 40.7B | |
-6.20% | 28.92B | |
+9.17% | 25.55B | |
-20.42% | 19.27B | |
+0.17% | 12.15B | |
+28.07% | 12.14B | |
-1.24% | 11.99B |
- Stock Market
- Equities
- TSHA Stock
- News Taysha Gene Therapies, Inc.
- Taysha Gene Therapies, Inc. announced that it has received $79.99982 million in funding from Astellas Pharma Inc., Audentes Therapeutics, Inc.